Summit Therapeutics (SMMT) FCF Margin (2017 - 2022)

Summit Therapeutics (SMMT) has 6 years of FCF Margin data on file, last reported at 3879.55% in Q3 2022.

• Quarterly FCF Margin fell 207962.0% year-over-year to 3879.55% in Q3 2022, while the trailing twelve-month figure through Jun 2023 was 20823.18% (down 1731550.0% YoY) and the FY2022 annual result came in at 5986.67%, down 195720.0% from the prior year.
• FCF Margin improved to 3879.55% in Q3 2022, from 8302.13% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 0.8% in Q4 2019 to a low of 33903.51% in Q2 2021.
• A 5-year average of 5925.43% and a median of 3704.78% in 2021 frame the typical range for FCF Margin.
• Annual changes were most pronounced in 2021 — FCF Margin sank 2292645 bps — and 2022, when it soared 2560138 bps.
• Tracing SMMT's FCF Margin over 5 years: stood at 662.52% in 2018, then surged by 100 bps to 0.8% in 2019, then tumbled by 540879 bps to 4335.68% in 2020, then rose by 15 bps to 3704.78% in 2021, then dropped by 5 bps to 3879.55% in 2022.
• The last three FCF Margin figures came in at 3879.55% (Q3 2022), 8302.13% (Q2 2022), and 7744.8% (Q1 2022), per Business Quant data.